Micafungin concentrations 100 mg daily in plasma and burn eschars in patients with severe burn injuries

  • Agrifoglio A
  • Asensio M
  • Sánchez M
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction Micafungin (MCF) is an echinocandin agent with broad activity against Candida spp., which are frequently isolated in blood and eschar cultures of burned patients, who present different pharmacokinetics (PK) characteristics. Peak plasma concentrations after the first and repeated doses of MCF were inversely correlated with % burned TBSA (Spearman's ? = -0.695 and -0.750 (P < 0.05)), respectively, but not with the time from burn injury. Patient % burned TBSA % FT ABSI MCF dose (mg/kg body weight) Plasma Cmax/Cmin after first dose (?g/ml) Plasma C/max/Cmin at steady state (?g/ml) Burn easchar tissue on day 5 (?g/ml) Days from admission to the start of MCF SOFA at the beginning of MCF LOS in BUCU (days) 1 35 20 9 1.3 8.6/0.8 7.4/1.0 2.3 38 1 75 2 40 35 8 2.0 8.5/1.1 9.4/1.8 <0.1 ?g/ml); SOFA, Sequential Organ Failure Assessment; TBSA, total body surface area.

Cite

CITATION STYLE

APA

Agrifoglio, A., Asensio, M., Sánchez, M., Galván, B., Herrero, E., Cachafeiro, L., … García de Lorenzo, A. (2015). Micafungin concentrations 100 mg daily in plasma and burn eschars in patients with severe burn injuries. Critical Care, 19(S1). https://doi.org/10.1186/cc14192

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free